Nebenwirkungen · Ocrevus
Ocrevus 920 mg solution for injection · Abschnitt 4.8 · PDF-Seite 44
HOS-134181 · Präparat HOS-097528
The majority of the neutrophil decreases were transient (only observed once for a given patient treated with ocrelizumab) and were Grade 1 (between<LLN and 1500 cells/mm3) and 2 (between 1000 and 1500 cells/mm3) in severity. Overall, approximately 1% of the patients in the intravenous ocrelizumab group had Grade 3 or 4 neutropenia. One patient with Grade 3 (between 500 and 1000 cells/mm3) and one patient with Grade 4 (< 500 cells/mm3) neutropenia required specific treatment with granulocyte- colony stimulating factor, and remained on ocrelizumab after the episode. Neutropenia can occur several months after the administration of ocrelizumab (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-16T16:45:00Z · SHA-256 1efa7a70ba1fb9e594cab6c3f7b0b93d20e409f3185d26e0f6619859477d1e37 · Passage 96c2cfa6730e24f9c103bd7b6e73b5991af3f58e57e7a04c96f5c77bcac66c64 · Zeichen 13293–13959 im Abschnitt